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Loss of the Merlin tumour suppressor causes abnormal de-differentiation and proliferation of Schwann cells and formation of
schwannoma tumours in patients with neurofibromatosis type 2. Within the mature peripheral nerve the normal development,
differentiation and maintenance of myelinating and non-myelinating Schwann cells is regulated by a network of transcription
factors that include SOX10, OCT6 (now known as POU3F1), NFATC4 and KROX20 (also known as Egr2). We have examined for
the first time how their regulation of Schwann cell development is disrupted in primary human schwannoma cells. We find that
induction of both KROX20 and OCT6 is impaired, whereas enforced expression of KROX20 drives both myelin gene expression
and cell cycle arrest in Merlin-null cells. Importantly, we show that human schwannoma cells have reduced expression of SOX10
protein and messenger RNA. Analysis of mouse SOX10-null Schwann cells shows they display many of the characteristics of
human schwannoma cells, including increased expression of platelet derived growth factor receptor beta (PDGFRB) messenger
RNA and protein, enhanced proliferation, increased focal adhesions and schwannoma-like morphology. Correspondingly, re-
introduction of SOX10 into human Merlin-null cells restores the ability of these cells to induce KROX20 and myelin protein zero
(MPZ), localizes NFATC4 to the nucleus, reduces cell proliferation and suppresses PDGFRB expression. Thus, we propose that
loss of the SOX10 protein, which is vital for normal Schwann cell development, is also key to the pathology of Merlin-null
schwannoma tumours.
Keywords: Schwann; merlin; SOX10; KROX20; schwannoma
Abbreviations: AMP = adenosine monophosphate; GFP = green fluorescent protein; P0 = myelin protein zero; PDGF = platelet
derived growth factor; MAPK = mitogen activated protein kinase; MBP = myelin basic protein
Introduction
The genetic condition neurofibromatosis type 2 is characterized
by formation of multiple tumours of the peripheral nervous
system. The predominant tumours formed are vestibular
schwannomas of the eighth cranial nerve (vestibulocochlear), but
also include cutaneous schwannomas, meningiomas and ependy-
momas (Hanemann, 2008). Neurofibromatosis type 2 is caused by
biallelic loss of the NF2 gene that encodes the tumour suppressor
protein merlin (NF2), which is also lost in all sporadic schwannoma
doi:10.1093/brain/aws353 Brain 2013: 136; 549–563 | 549
Received August 9, 2012. Revised November 7, 2012. Accepted November 12, 2012
 The Author (2012). Published by Oxford University Press on behalf of the Guarantors of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which
permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
tumours (Rouleau et al., 1993; Trofatter et al., 1993). Research
has shown that merlin acts to ensure cell–cell contact inhibition of
growth and regulates protein ubiquitination in the nucleus through
interaction with DCAF1 (McClatchey and Giovannini, 2005; Curto
et al., 2007; Lallemand et al., 2009; Li et al., 2010). Loss of merlin
in cultured Schwann cells leads to altered morphology, enhanced
proliferation and over activation of multiple signalling pathways
including Rac GTPase, extracellular regulated kinase (ERK), c-Jun
N-terminal kinase (JNK) and phosphatidyl inositol-3 kinase (PI-3
kinase) MAP kinase pathways (Shaw et al., 2001; Kaempchen
et al., 2003; Ammoun et al., 2008). During Schwann cell devel-
opment, a number of signalling pathways and transcription factors
regulate axon–Schwann cell interaction, cell cycle withdrawal and
differentiation of Schwann cells within peripheral nerves (Jessen
and Mirsky, 2005; Pereira et al., 2012), and the impact of
merlin loss on these regulators of normal Schwann cell differenti-
ation has not yet been investigated. The zinc finger transcription
factor KROX20 is essential for the differentiation of myelinating
Schwann cells and regulates both cell cycle withdrawal and myelin
gene expression (Topilko et al., 1994; Zorick et al., 1999;
Parkinson et al., 2004). Expression of KROX20 in turn is regulated
by a number of other transcription factors such as SOX10, OCT6,
NFATC4 and YY1, which bind and co-operatively activate the
myelinating Schwann cell enhancer of the KROX20 promoter
(Ghislain and Charnay, 2006; Kao et al., 2009; He et al., 2010;
Kipanyula et al., 2012). In addition to its role in myelin gene
regulation, in synergy with KROX20, SOX10 functions to regulate
Schwann cell proliferation and controls the dynamics of Schwann
cell–axon interactions during development (Finzsch et al., 2010).
SOX10 is both essential for the generation of Schwann cell pre-
cursors from the neural crest (Britsch et al., 2001) and the sequen-
tial induction of OCT6 and KROX20 during myelination (Finzsch
et al., 2010). Given that the key characteristics of human schwan-
noma tumours are loss of cell differentiation, loss of axonal con-
tact and increased cell proliferation, we have investigated this
transcriptional network in these cells.
As a first step, we tested both the regulation and function of
KROX20 in human Merlin-null schwannoma cells. We found that
the induction of both KROX20 and OCT6 is impaired in these cells,
whereas enforced expression of KROX20 induces cell cycle arrest
and differentiation identically in human control Schwann cells and
Merlin-null schwannoma cells. As SOX10 is key in the regulation of
both OCT6 and KROX20, we measured the levels of SOX10 in
schwannoma cells and found reduced levels of SOX10 messenger
RNA and protein in all the tumours we analysed (n = 17). In keeping
with a role for SOX10 in these tumours, SOX10 re-expression re-
stores the ability of these cells to induce Kroz-20, relocalizes NFATC4
to the nucleus and drives myelin gene expression. Human schwan-
noma cells express raised levels of PDGFRB and consequently show
increased signalling and proliferation in response to platelet derived
growth factor (PDGF) (Ammoun et al., 2008). We find that
re-expression of SOX10 in human schwannoma cells reduces
PDGFRB expression and consequently PDGF-induced signalling
and proliferation. To separately study the roles of SOX10 and
merlin, we have used conditional mouse knockouts for both genes
together with small interfering RNA knockdown of merlin in
Schwann cells. We demonstrate that loss of merlin alone, both
in vitro and in vivo, does not reduce SOX10 levels in Schwann
cells. Similarly, restoration of merlin expression in human
schwannoma cells does not rescue SOX10 expression. Analysis of
SOX10-null mouse Schwann cells shows that loss of SOX10 alone
appears to give many of the phenotypes of human schwannoma
cells, namely increased levels of PDGFRB, increased cell proliferation,
schwannoma-like morphology with increased focal adhesions and
the failure to myelinate in vitro (Flaiz et al., 2009). These findings
link, for the first time, the processes of normal cell differentiation
and tumourigenesis in Schwann cells and demonstrate that loss
of both merlin and SOX10 contribute to the aberrant phenotype
of human schwannoma cells.
Materials and methods
Reagents
Adenoviruses expressing green fluorescent protein (GFP), KROX20/GFP,
Cre recombinase, JNK-binding domain of JNK-interacting protein 1
(JIP-1) and 169 c-Jun have been described elsewhere (Parkinson
et al., 2001, 2004, 2008). Adenoviruses expressing NF2/GFP (Xiao
et al., 2005) and dominant negative Rac1 (Wojciak-Stothard et al.,
2001) were kind gifts from J. Testa (Fox Chase Cancer Centre,
Philadelphia, USA) and A. Ridley (King’s College London, UK), respect-
ively. The SOX10 adenoviral construct was generated using a C-Terminal
haemagglutinin (HA)-tagged human SOX10, using the AdEasyTM system
(He et al., 1998) to generate an adenovirus co-expressing GFP and
HA-tagged SOX10. Antibodies against OCT6 (sc-11661), NFATC4
(sc-13036), Rho GDI (sc-359), Beta2a tubulin (sc-134229) and merlin
(sc-55575) were from Santa Cruz Biotechnology (Wembley, UK). Guinea
pig and rabbit antibodies against SOX10 were as described (Stolt et al.,
2003; Maka et al., 2005). Phospho-NFB (Ser276) p65 antibody (#3037),
phospho-CREB (Ser133, #9198) and PDGFRB (#3169) were obtained
from New England Biolabs. S100b antibodies were from Dako, Ki67
antibodies from Abcam, KROX20 antibodies were from Cambridge
Bioscience, phospho-ERK1/2 (V8031) antibody was from Promega and
paxillin (5H11) antibody from Millipore. Antibody to periaxin was a gift
from P. Brophy (University of Edinburgh, UK), and antibody to myelin
protein zero (MPZ or P0) a gift from J. Archelos (Medical University of
Graz, Austria). Biotinylated anti-guinea pig, anti-goat, anti-mouse and
anti-rabbit were obtained from Vector laboratories. Alexa Fluor fluor-
escently conjugated anti-rabbit, mouse or goat IgGs and fluorescently
conjugated streptavidin were from Life Technologies (Paisley, UK).
Superfrost glass slides were from VWR Merck. All reagents for small
interfering RNA knockdown of merlin were obtained from Qiagen
(Crawley, UK).
Preparation of Schwann cell cultures
Schwann cells were prepared from the sciatic nerve and brachial plexus
of post-natal day 3 rodents as previously described (Brockes et al.,
1979). Human Schwann cells were isolated from nerve donors and
schwannoma cells from tumour samples of patients with neuro-
fibromatosis type 2 (following informed consent). Neurofibromatosis
type 2 diagnosis was established using criteria set down in the NIH
Consensus Conference (National Institutes of Health Consensus
Development Conference, 1988; Mulvihill et al., 1990). Cells were
harvested and cultured as previously described (Hanemann et al.,
1998; Rosenbaum et al., 1998). All experiments were performed in
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serum-free supplemented medium known as defined medium (Jessen
et al., 1994; Parkinson et al., 2008).
Immunocytochemistry, western
blotting, polymerase chain reaction
and adenoviral infections
Immunostaining and counting were performed as previously described
(Parkinson et al., 2001, 2003, 2004, 2008). Anti-SOX10 (both anti-
bodies at 1:1000), anti-OCT6 (1:150), anti phospho-NFB (Ser276) p65
(1:100), phospho-CREB (1:100), NFATC4 (1:1000) and PDGFRB
(1:100) primary antibodies were incubated overnight at 4C.
Biotinylated secondary antibodies (1:200), anti-guinea pig, anti-goat
and anti-rabbit, were incubated at room temperature for 45 min and
the streptavidin-568 third layer (1:500) incubated for 30 min at room
temperature. Confocal imaging was performed using the Zeiss meta
510 confocal microscope and the Zeiss LSM software (Zeiss).
Fluorescence microscopy was performed on a Nikon Eclipse 80i.
Unless otherwise stated, western blotting, PCR and adenoviral infec-
tions were performed as previously described (Parkinson et al., 2001,
2003, 2004, 2008; Kaempchen et al., 2003; Flaiz et al., 2007). For
semi-quantitative PCR, the following primers were used: 18S rRNA
For, CAGCCACCCGAGATTGAGCA, Rev, TAGTAGCGACGGGCGGTG
TG; SOX10 For: CAGGCGAGCTGGGCAAGGTCAAG, Rev: CTGCCT
GAGCCCACACCATGAAG; PDGFRB For: CGAGTTGGACCTGAACA
TGAC, Rev: CGCACAATCTCGATCTTTCTC; CD44 For: TGAATATAA
CCTGCCGCTTTG, Rev: GTCATACTGGGAGGTGTTGGA.
Schwann cell differentiation and
proliferation assays
For myelination assays, defined medium was supplemented with 1 mM
dibutyryl cAMP for 48 h unless otherwise stated. Human Schwann and
schwannoma cells were infected with adenoviruses, in defined medium
without forskolin, for 24 h before cAMP stimulation in fresh defined
medium. For proliferation assays in human schwannoma cells, 20 ng/
ml NRG1, 100 ng/ml IGF-1 or 100 ng/ml PDGF-DD was added to
fresh defined medium for 24 h or 72 h after the initial adenoviral in-
fection. For proliferation assays in mouse Schwann cells defined
medium was supplemented with 10 ng/ml PDGF-DD with or without
2 mm forskolin for 48 h.
Transgenic mice
Transgenic mouse breeding and experiments were performed follow-
ing guidelines from the UK Home Office. Mice with the conditional
SOX10fl/fl allele have been described (Finzsch et al., 2010), and mice
with the conditional NF2fl/fl allele (Giovannini et al., 2000) were
obtained from the Riken BioResource Centre (Experimental Animal
Division, Japan). For in vitro analysis of null cells, mouse Schwann
cells were prepared from the sciatic nerves of either Sox10fl/fl or
Nf2fl/fl mouse pups and SOX10 or merlin gene expression removed
in culture by infection with Cre-recombinase expressing adenovirus.
Schwann cells from the same culture were infected with GFP virus
and used as a control. Mice expressing Cre recombinase under the
control of the P0 promoter (mTOTA P0-Cre) have been previously
described (Feltri et al., 1999). For analysis of Merlin-null sciatic
nerve in vivo, NF2fl/fl mice were crossed with P0-Cre mice to generate
NF2fl/wt Cre + animals that were then back-crossed to NF2fl/fl mice to
generate control (NF2fl/fl Cre) and Merlin-null (NF2fl/fl Cre + ) sciatic
nerve for analysis.
Small interfering RNA knockdown
Merlin was knocked down in Schwann cells using 3 nM of validated
small interfering RNA oligos Rn_Nf2_2 and Rn_Nf2_3 in combination.
Alternatively, 3 nM Allstars negative control was used as a scrambled
control. Small interfering RNA/lipid complexes were prepared using
6 ml of HiPerfect reagent and incubated with cell cultures for 20 h.
Transfection was performed twice at 0 and 48 h, and protein expres-
sion assayed a further 24 or 48 h later.
Fluorescent immunohistochemistry
Transverse 7-mm thick cryostat sections of schwannoma and control
peroneal nerve were fixed with 4% paraformaldehyde on Superfrost
plus glass slides. Sections were then stained sequentially with antibo-
dies against SOX10 (1:1000) and S100b (1:100) following the fluor-
escent immunocytochemistry protocol.
Scanning electron microscopy
For scanning electron microscopy, mouse Schwann cells were cultured
on glass coverslips and infected with GFP or Cre expressing adenovirus
as above. Forty-eight hours after addition of adenovirus, coverslips
were fixed in 2.5% w/v glutaraldehyde, diluted in 0.2 M sodium caco-
dylate buffer, at room temperature for 2 h and then washed twice in
0.2 M sodium cacodylate buffer. Coverslips were washed in 30%,
50%, 70%, 90% and 100% absolute ethanol for 15 min each at
room temperature. Samples then underwent critical point drying
through CO2 in a K850 Critical Point Dryer (Emitech), and coverslips
were mounted on support stubs and gold coated (nominal thickness
10 nm) in a K550 Sputter Coater (Emitech). Samples were imaged on a
JSM-5600LV scanning electron microscope (JEOL Ltd.) operated at
15 kV, with an 11 mm working distance and at 1000 or 2000
magnification.
Statistics
For all experiments, n = 3 was used unless otherwise stated. All graphs
display the arithmetic mean with error bars representing one standard
error of the mean. P-values were calculated using a Student t-test and
are denoted on figures as: *P5 0.05, **P5 0.01 and ***P5 0.005.
For all cell differentiation and proliferation assays, 200 cells were
counted in duplicate. In adenoviral experiments, the number of posi-
tive cells was divided by the number of GFP positive cells. For all other
experiments, the number of positive cells was divided by the number
of Hoechst positive cells. A minimum of 500 cells were counted for
SOX10 positivity in each cryostat section.
Results
KROX20 drives myelin gene expression
in Merlin-null schwannoma cells
It has been well characterized that KROX20 is the key regulator of
Schwann cell myelination. Enforced expression of KROX20 in vitro
is sufficient to drive increased expression of compact myelin pro-
teins (P0 and MBP), myelin associated proteins (myelin associated
glycoprotein and periaxin) and essential enzymes in myelin lipid
synthesis (Nagarajan et al., 2001; Parkinson et al., 2003).
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KROX20 expression also downregulates expression of the myelin-
ation inhibitory transcription factors c-Jun and Sox2 (Parkinson
et al., 2004, 2008; Le et al., 2005). As a first step in this analysis
of Merlin-null schwannoma cells, we tested whether these events
downstream of KROX20 could be normally regulated in these
tumour cells. No significant basal differences in the expression of
myelin proteins or negative myelin-regulators were observed in
schwannoma cells. To investigate whether KROX20 could drive
myelination in schwannoma cells, we infected primary human
schwannoma (NF2/) and control Schwann (NF2 + / + ) cells
with adenoviral constructs co-expressing KROX20 and GFP or
GFP alone. After KROX20 expression, we assessed, by immuno-
labelling and western blotting, the induction of myelin targets and
downregulation of c-Jun expression.
KROX20 was able to drive strong upregulation of the myelin
protein P0 and the myelin marker periaxin in both wild-type
Schwann cells and Merlin-null schwannoma cells, shown by both
fluorescent immunocytochemistry and western blotting (all
P5 0.02). Similarly, KROX20 was also able to downregulate the
inhibitory transcription factor c-Jun in Merlin-null schwannoma
cells (P50.001) (Fig. 1). The regulation of P0, periaxin and
c-Jun by KROX-20 in human Schwann and schwannoma cells
was indistinguishable from that seen in primary rat Schwann
cells (data not shown). These data suggest that once expressed,
KROX-20 is apparently fully able to drive the downstream mye-
lination programme in Merlin-null schwannoma cells.
KROX20 expression inhibits the
proliferation of Merlin-null
schwannoma cells
In addition to controlling myelin gene expression, KROX20 has
been shown to regulate the proliferation of Schwann cells, inhibit-
ing the proliferation of cells in response to mitogens such as
beta-neuregulin (NRG1) (Zorick et al., 1999; Parkinson et al.,
2004). Loss of merlin causes schwannoma cells to proliferate at
an increased basal rate, to lose cell–cell contact dependent inhib-
ition of cell proliferation and continue to grow in overlapping
layers past confluency in vitro (Lallemand et al., 2003; Curto
et al., 2007; Flaiz et al., 2007, 2008). This proliferation could
be driven by either PDGF or IGF-1, which have both been
shown to be mitogenic for schwannoma cells in vitro (Ammoun
et al., 2008, 2012).
To test whether KROX20 effectively controls proliferation in
schwannoma cells, primary human Merlin-null cells were infected
with either GFP- or KROX20/GFP-expressing adenoviruses in
defined medium and then treated with the Schwann cell mitogens
NRG1 (10 ng/ml), PDGF-DD (100 ng/ml) or IGF-1 (100 ng/ml).
Proliferation was measured by immunofluorescence using an anti-
body against Ki-67, which has a punctate nuclear stain in prolif-
erating cells (Fig. 2). Basal proliferation of schwannoma cells in
defined medium alone was 2.3  0.5%, which was increased by
NRG1, PDGF or IGF-1 addition to 8.1  1.1, 8.7  1.1 and
11.2  2.1%, respectively, in control GFP infected schwannoma
cells (Fig. 2). This proliferation was dramatically and significantly
reduced to 51% with all mitogens in KROX20-expressing
schwannoma cells (Fig. 2; NRG1, P50.001; PDGF, P50.001;
IGF-1, P = 0.002; n = 4). KROX20 therefore effectively controls
proliferation of schwannoma cells in mitogen-stimulated condi-
tions. In conclusion, we saw that enforced KROX20 expression
in Merlin-null schwannoma cells is sufficient to drive myelin
gene expression, downregulate inhibitors of myelination and to
inhibit the proliferation of schwannoma cells in response to a
range of mitogens. These findings implied that the differentiation
network downstream of KROX20 is intact in Merlin-null schwan-
noma cells; therefore, we next investigated the regulatory events
upstream of KROX20 in these cells.
Impaired induction of KROX20 and
OCT6 in schwannoma cells
During Schwann cell myelination in vivo, expression of KROX20 is
controlled by a complex signalling cascade involving the transcrip-
tion factors OCT6, SOX10, YY1 and NFATC4, as well as through
activation of the G-protein coupled receptor GPR126 (Topilko
et al., 1994; Jaegle et al., 1996; Kao et al., 2009; Monk et al.,
2009, 2011; Finzsch et al., 2010; He et al., 2010). This process of
myelination can be mimicked in vitro by addition of cyclic AMP,
which causes Schwann cell flattening and upregulation of myelin
proteins (e.g. P0, myelin basic protein and periaxin), myelin lipids
(e.g. O4) and myelinating transcription factors (e.g. OCT6 and
KROX20) (Morgan et al., 1991; Parkinson et al., 2008). The abil-
ity of Merlin-null schwannoma cells to upregulate KROX20 in
response to cyclic AMP was tested by incubating primary human
Schwann and schwannoma cells in defined medium alone or
in defined medium supplemented with 1 mM of the non-
hydrolysable cyclic AMP analogue dibutyryl-cAMP (hereafter
referred to as cAMP) for 24, 48 and 72 h and examining
KROX20 induction by immunofluorescence and western blotting.
Human control Schwann cells displayed no detectable KROX20
expression in basal conditions, but dramatically induced KROX20
on cAMP treatment, peaking at 34.8  4.2% of nuclei positive for
KROX20 at 72 h (Fig. 3 at 48 h and Supplementary Fig. 1). In
contrast, Merlin-null schwannoma cells from seven independent
tumours were significantly reduced in their ability to induce
KROX20 protein at all time points examined (Fig. 3 and data
not shown) peaking at only 9.1  2.3% at 72 h, with a signifi-
cantly decreased induction at 24 h (P = 0.037), 48 h (P5 0.001)
and 72 h (P50.001). Schwannoma cells from three of these tu-
mours displayed an absolute block in KROX20 induction, with
51% of cells KROX20 positive after any duration of cAMP treat-
ment. This result was confirmed by western blotting at the 48 h
time point in control human Schwann and schwannoma cells,
again showing no apparent induction of KROX20 in Merlin-null
schwannoma cells from a further two schwannoma tumours
(Fig. 3). The myelinating Schwann cell marker periaxin is also
induced by cAMP in Schwann cells (Parkinson et al., 2003) and
we found that the induction of periaxin was also significantly
blocked in Merlin-null schwannoma cells at all timepoints exam-
ined (Fig. 3, 48 h and Supplementary Fig. 1, P50.001, 72 h).
KROX20 induction may be inhibited by increased activity of the
ERK1/2 and JNK1/2 MAP kinase pathways (Harrisingh et al.,
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Figure 1 Kroz-20 induces periaxin and P0 and downregulates c-Jun expression in both control and Merlin-null human Schwann cells.
(A–H) Immunofluorescence of control Schwann + / + (A, B, E and F) and Merlin-null schwannoma / (C, D, G and H) cells infected
with control GFP (A–D) or GFP/KROX20 (E–H, K20) expressing adenoviruses showing equal induction of periaxin (Prx) protein in both
control and Merlin-null cells (F and H). (I–P) Immunofluorescence of control + / + (I, J, M and N) and Merlin-null / (K, L, O and P)
cells infected with GFP and GFP/KROX20 (K20) expressing adenoviruses, showing down regulation of c-Jun in both control and
Merlin-null cells (N and P). Scale bars = 20 mm. (Q and R) Graphs showing percentage periaxin/GFP (Q) and c-Jun/GFP (R) positive control
Schwann ( + / + ) and schwannoma (/ ) cells following infection with GFP control and GFP/KROX20 expressing adenoviruses. (S)
Western blot showing similar upregulation of periaxin and P0 protein and downregulation of c-Jun expression by KROX20 in both control
Schwann ( + / + ) and Merlin-null schwannoma cells (/ ).
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2004; Ogata et al., 2004), and both pathways have been shown
to be elevated in Merlin-null schwannoma cells (Ammoun et al.,
2011). We therefore tested whether inhibition of either or both of
these pathways would restore KROX20 induction. Experiments
using a JNK1/2 inhibitor (SP600125), expression of the JNK-bind-
ing domain of JIP-1, both of which have previously been shown to
inhibit JNK activity in Schwann cells (Parkinson et al., 2004), or
even expression of dominant negative c-Jun (169 c-Jun;
Parkinson et al., 2001) did not restore KROX20 induction in
schwannoma cells. Similarly, inhibition of the MEK/ERK pathway
by U0126 or AZD6244, the PI3-kinase pathway using BEZ235, or
even use of the ErbB2 inhibitor Lapatinib or the PDGFR inhibitors
Nilotinib or Sorafenib, all of which inhibit schwannoma cell prolif-
eration at the concentrations used, were unable to increase
KROX20 induction in response to cAMP in schwannoma cells
(Supplementary Fig. 2 and data not shown). Similarly, both
mouse and human Merlin-null cells show increased GTP loading
of Rac, and such enhanced Rac activity has been shown to block
elongation of schwannoma cells along dorsal root ganglion axons
in co-culture assays, an early step in myelination (Nakai et al.,
2006). Inhibition of Rac activity by adenovirally mediated expres-
sion of dominant negative N17-Rac also failed to rescue KROX20
expression in schwannoma cells in response to cAMP (data not
shown).
Next, we tested whether there was normal induction of the POU
domain transcription factor OCT6 in Merlin-null schwannoma cells.
Forty-eight hours after addition of cAMP to control human
Schwann cells, we observed induction of nuclear OCT6 by
immunocytochemistry and western blotting, which was significantly
(P = 0.003) blocked in Merlin-null schwannoma cells (Fig. 3).
Phosphorylation and activation of NFB and CREB following
cAMP treatment are thought to be important for the induction
of OCT6 and KROX20, respectively (Nickols et al., 2003;
Arthur-Farraj et al., 2011). Using phospho-specific antibodies for
the p65 subunit of NFB (Ser276) and CREB (Ser133), we mea-
sured the response to cAMP in control and Merlin-null schwan-
noma cells. Analysis by immunocytochemistry with these
antibodies after cAMP addition showed an identical amplitude
and duration of activation (i.e. phosphorylation) of NFB and
CREB in control Schwann and Merlin-null schwannoma cells
(Supplementary Fig. 3). Additionally, the zinc finger transcription
factor YY1 has also been shown to regulate KROX20 expression
during myelination. Analysis by immunolabelling showed clear nu-
clear YY1 expression in both control Schwann and Merlin-null
schwannoma cells (data not shown). These experiments identify
the regulation of both OCT6 and KROX20 by cyclic AMP as ab-
normal in Merlin-null schwannoma cells.
SOX10 levels are reduced in Merlin-null
schwannoma cells in vitro and in vivo
The high mobility group transcription factor SOX10 is first ex-
pressed in the neural crest and is required for Schwann cell spe-
cification and subsequent myelination in the peripheral nervous
system (Britsch et al., 2001; Finzsch et al., 2010). The control of
both KROX20 and OCT6 have been shown to be dependent on
Figure 2 KROX20 halts the proliferation of Merlin-null schwannoma cells. (A–D) Human Merlin-null schwannoma cells were infected
with GFP (A and B) or GFP/KROX20 (K20) adenoviruses (C and D) for 24 h and then treated with 20 ng/ml of NRG-1 ( + NRG-1) for
a further 24 h. Cells were fixed and immunolabelled with antibodies against Ki-67. Arrows in A and B indicate Ki-67 positive nuclei.
Scale bar = 20 mm. (E) Graph showing that KROX20 expression causes a significant decrease in schwannoma cell proliferation in response
to NRG-1 (P50.001), PDGF (P50.001) or IGF-1 (P = 0.002).
554 | Brain 2013: 136; 549–563 R. D. S. Doddrell et al.
SOX10 expression (Ghislain and Charnay 2006; Reiprich et al.,
2010; Jagalur et al., 2011); therefore, we next measured SOX10
levels in vitro in control and Merlin-null schwannoma cells and
in vivo by analysis of cryostat sections of control human nerve
and schwannoma tumour samples. Figure 4 shows the results of
immunocytochemistry and western blotting of human Schwann
and schwannoma cells. In vitro, control Schwann cells displayed
a uniform intense nuclear expression in all cells. In contrast, both
schwannoma cells in vitro and sections of schwannoma tumours
showed a consistent decreased expression in all cells or a hetero-
geneous staining pattern with some cells expressing SOX10 and
some containing no detectable SOX10 (n = 8; Fig. 4). These find-
ings were confirmed with two separate SOX10 antibodies. In total,
we analysed cultured cells from eight schwannoma tumours and
cryostat sections from a further six independent tumours and
observed a significant reduction of SOX10 in all samples analysed.
Counts of SOX10-positive nuclei in control nerve and schwan-
noma sections showed overall a significant (60.3%, P5 0.001)
decrease in the percentage of SOX10-positive nuclei
(Supplementary Fig. 4). Western blotting of cell extracts from
three further independent schwannoma cell cultures compared
with three control human primary Schwann cell extracts also
showed a variable, but consistent, reduction in SOX10 expression
in Merlin-null schwannoma cells. Thus, in total, we have analysed
17 human schwannoma samples, all of which showed a reduction
in SOX10 protein levels. Similarly, we observed a reduction of
SOX10 messenger RNA levels in schwannoma cells compared
with control Schwann cells (Fig. 4).
Figure 3 Merlin-null schwannoma cells do not induce OCT6 or KROX20 in response to cyclic AMP. (A–F) Impaired induction of OCT6 in
schwannoma cells. Control (NF2 + / + ) and Merlin-null (NF2/ ) cells were treated for 48 h with 1 mM cAMP and OCT6 levels
measured by immunolabelling (A–D) and western blotting (F). Note clear induction of OCT6 in nuclei of control ( + / + ) cells (C), whereas
no OCT6 is observed in Merlin-null (/ ) cells (D). Scale bar = 20 mm (E). Graph of percentage OCT6-positive Schwann and schwan-
noma cells in response to cAMP. (F and G) Western blot showing lack of OCT6 (F) and KROX20 (G) induction in response to cAMP at
48 h. (H and I) Graphs showing percentage KROX20 (H) and periaxin (I) positive control (NF2 + / + ) and Merlin-null (NF2 / ) cells
after cAMP treatment (48 h). DM = defined medium control.
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Re-expression of SOX10 in human
Merlin-null schwannoma cells rescues
KROX20 and P0 induction
Having identified a consistent reduction in SOX10 levels in
schwannoma cells as a possible cause of decreased KROX20 and
OCT6, we measured the effects of haemagluttinin-tagged SOX10
re-expression in human schwannoma cells. Immunolabelling and
western blotting of schwannoma cells with either haemagluttinin
or SOX10 antibodies showed strong nuclear expression of SOX10
in cells following adenoviral infection (Fig. 5 and data not shown).
Next, we tested whether reintroduction of SOX10 into schwan-
noma cells would allow induction of Krox-20 in response to cAMP.
SOX10 expression was sufficient, in the absence of cAMP, to
induce KROX20 in a small percentage of schwannoma cells
(P = 0.001 versus controls), which was greatly enhanced by the
addition of cAMP (P50.001 versus controls). In addition, we also
observed the induction of P0 protein in these cells (Fig. 5).
SOX10 re-expression causes nuclear
localization of NFATC4 in
schwannoma cells
Signalling through the calcineurin/NFAT pathway has also recently
been shown to be required for KROX20 induction and myelination
(Kao et al., 2009; Kipanyula et al., 2012). Although Schwann cells
express NFATC1–C4 (Kipanyula et al., 2012), only NFATC4 has
been shown to bind to the myelinating Schwann cell enhancer of
the KROX20 gene and drive KROX20 expression in Schwann cells
(Kao et al., 2009). We therefore examined the levels and local-
ization of NFATC4 in schwannoma cells infected with control GFP
and SOX10/GFP expressing adenoviruses with or without cAMP
treatment. This analysis showed that, in contrast to control GFP
virus-infected cells, SOX10 reintroduction causes nuclear localiza-
tion of NFATC4 that is further boosted upon cAMP treatment
(P5 0.001). Western blotting demonstrated that this nuclear lo-
calisation occurred without any SOX10 driven increase in NFATC4
protein expression (Fig. 5). In addition to this, expression of
SOX10 also seems to cause a shift in the molecular weight of
NFATC4, which is consistent with its potential dephosphorylation,
and nuclear localization, in response to SOX10 expression (Kao
et al., 2009).
Loss of SOX10 expression in
schwannoma cells is independent
of Merlin loss
Having observed the clear loss of SOX10 in schwannoma cells and
the effects of SOX10 re-expression in these cells, we next tested
whether SOX10 expression is directly controlled by merlin in
Figure 4 Expression of SOX10 protein and messenger RNA is reduced in Merlin-null human schwannoma cells. (A–F) Cryostat sections of
control human peroneal nerve ( + / + , A and B) and human schwannoma tumours (/ , C–F) stained with SOX10 antibody and the
Schwann cell marker S100b (S100). Nuclei are counterstained with Hoechst dye (Ho). Almost all nuclei in control nerve (A and B) are
SOX10 positive. For the tumour shown in panels C and D, a mosaic pattern is observed with many cells being SOX10 negative. For the
tumour shown in panels E and F, almost no SOX10 stain is observed. Scale bar = 20 mm. (G–J) Immunolabelling of dissociated control
Schwann ( + / + , G and H) and Merlin-null schwannoma (/ , I and J) cells in culture with SOX10 antibody. Note mosaic pattern in
SOX10 stain in panel J; arrows show SOX10-negative cells in I and J. Scale bar = 20 mm. (K) Western blot analysis of three independent
human control ( + / + ) and Merlin-null (/ ) schwannoma tumour samples. Note reduction of SOX10 expression in all tumour samples.
(L) Semi-quantitative PCR showing reduction of SOX10 messenger RNA in two independent Merlin-null tumours (/ ) compared with
normal Schwann cell controls ( + / + ).
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Figure 5 Re-introduction of SOX10 into Merlin-null human schwannoma cells rescues induction of KROX20, P0 and NFATC4. (A–H)
Merlin-null cells were infected with GFP (A–D) and GFP/SOX10 (E–H) expressing adenoviruses and either maintained in defined medium
alone (A, B, E and F) or defined medium plus 1 mM cAMP (C, D, G and H). Note that SOX10 expression alone is sufficient to drive
KROX20 expression in a small number of cells (F, I and K), which is further enhanced by cAMP treatment (H, I and K). Scale bar = 20 mm.
(I) Percentage KROX20-positive cells in GFP- and SOX10-infected schwannoma cells. (J) Graph showing that SOX10-null mouse Schwann
cells do not induce KROX20 in response to cAMP + NRG-1, but re-expression of SOX10 restores KROX20 induction. (K) Western blot
showing regulation of KROX20 and P0 by SOX10 in Merlin-null cells. Probing with HA antibody detects adenovirally mediated SOX10
expression. (L–S) Re-expression of SOX10 in Merlin-null cells restores nuclear localization of NFATC4. Merlin-null cells were infected with
GFP- (L–O) and GFP/SOX10- (P–S) expressing adenoviruses and either maintained in defined medium alone (L, M, P and Q) or defined
medium plus 1 mM cAMP (N, O, R and S). Scale bar = 20 mm. (T) Percentage NFATC4-positive cells in GFP- and GFP/SOX10-infected
schwannoma cells. (U) Graph showing that SOX10-null mouse Schwann cells do not induce nuclear localization of NFATC4 in response to
cAMP + NRG-1, but re-expression of SOX10 restores NFATC4 relocalization. (V) Western blot showing expression of NFATC4 in GFP and
GFP/SOX10 infected schwannoma cells. DM = defined medium.
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Schwann cells. To do this, we used a number of in vitro and
in vivo approaches. Firstly, using small interfering RNA, we
silenced merlin expression in rat Schwann cells and measured
SOX10 expression by western blot and immunocytochemistry.
No effect on SOX10 levels was seen at either 72 or 96 h time
points after transfection, despite almost complete silencing of
merlin (Fig. 6). Next, we analysed Merlin-null Schwann cells,
either in vitro by infection of NF2fl/fl Schwann cells (Giovannini
et al., 2000) with adenovirus expressing Cre recombinase, or
in vivo by analysis of Merlin-null sciatic nerve prepared by breed-
ing NF2fl/fl mice with P0-Cre expressing mice to specifically ablate
merlin expression in Schwann cells of the nerve (Feltri et al.,
1999). Using both paradigms, we did not observe a reduction of
SOX10 protein expression in Merlin-null Schwann cells, either by
western blot or staining of nerve cryosections (Fig. 6), demonstrat-
ing that loss of merlin does not directly lead to lower SOX10
levels. Finally, we performed experiments to reintroduce merlin
into human schwannoma cells and measure levels of SOX10.
Adenovirally mediated re-expression of merlin did not increase
SOX10 levels in cells after 48 h as measured by either immuno-
cytochemistry or western blot in human schwannoma cells (Fig. 6).
Loss of SOX10 alone results in
phenotypes typical of human
schwannoma cells
Loss of SOX10 in vivo leads to abnormalities in Schwann cell–axon
interactions, a complete block in myelination and increased
post-natal proliferation of Schwann cells in peripheral nerves
(Finzsch et al., 2010; Bremer et al., 2011). To characterize changes
in Schwann cells that are SOX10-dependent, we next prepared,
in vitro, SOX10-null Schwann cells by treatment of SOX10fl/fl cells
with Cre-recombinase expressing adenovirus. In vitro SOX10-null
cells show a flattened non-bipolar morphology and increased focal
adhesions as measured by paxillin immunolabelling (Fig. 7), both
phenotypes of human schwannoma cells (Rosenbaum et al., 1998;
Flaiz et al., 2009). Similar to human schwannoma cells, SOX10-null
cells show significantly increased (P = 0.03) adhesion in a cell adhe-
sion assay (Utermark et al., 2003) compared with control GFP virus
infected cells (Supplementary Fig. 5). To confirm our idea that loss of
SOX10 in Merlin-null human schwannoma cells causes reduced
KROX20 induction, we performed in vitro myelination assays as
Figure 6 Regulation of SOX10 expression in Schwann cells is independent of merlin. (A) Western blot of rat Schwann cells transfected
with control scrambled (asterisk) or NF2 small interfering RNA (NF2) at 72 h and 96 h after transfection; untransfected cells ( ). Note that
knockdown of merlin at both 72 and 96 h time points, but no decrease in SOX10 protein expression. (B) Western blot of NF2fl/fl mouse
Schwann cells infected with control GFP- or Cre-expressing adenoviruses, 72 h after infection. (C) Western blot of control (NF2fl/fl Cre )
and Merlin-null (NF2fl/fl Cre + ) post-natal Day 6 (P6) mouse sciatic nerve, showing no reduction of SOX10 protein levels. (D–G) Cryostat
sections from control ( + / + ; D and E) and Merlin-null (/ ; F and G) post-natal Day 6 mouse sciatic nerve shows no difference in
nuclear SOX10 stain (E and G); nuclei are counterstained with Hoechst dye (Ho; D and F). Scale bar = 100mm. Insets in panels D–G show
higher magnification views of cells, confirming that SOX10 is localized to the nuclei of cells. (H–L) Re-introduction of merlin into
Merlin-null human schwannoma cells does not restore expression of SOX10. Human schwannoma cells were infected with either GFP
control- (H, I) or GFP/Merlin- (J and K) expressing adenoviruses and immunolabelled with SOX10 antibodies 48 h after infection (I and K).
Scale bar = 20 mm. (L) Western blot showing human schwannoma cells 48 h after infection with control GFP or merlin (NF2) expressing
adenoviruses. Merlin re-introduction into Merlin-null human schwannoma cells does not increase SOX10 expression.
558 | Brain 2013: 136; 549–563 R. D. S. Doddrell et al.
described (Arthur-Farraj et al., 2011) with control and Sox10-null
mouse Schwann cells. SOX10-null Schwann cells displayed minimal
NFATC4 nuclear localization and KROX20 induction that was
significantly increased by SOX10 reintroduction (P = 0.003,
NFATC4; P50.001, KROX20) (Fig. 5). Similarly, in line with the
in vivo evidence (Finzsch et al., 2010), SOX10-null mouse
Schwann cells fail to induce OCT6 in response to cAMP plus neur-
egulin (data not shown).
In addition, human Merlin-null schwannoma cells show a range of
phenotypes, but two of the key changes in these cells are increased
expression of PDGFRB, causing increased proliferation of cells, and
the CD44 cell surface glycoprotein, which is involved in cell adhesion
and migration (Morrison et al., 2001; Hanemann et al., 2006; Bai
et al., 2007; Ammoun et al., 2008). To study whether the regulation
of PDGFRB and CD44 in Schwann cells is SOX10-dependent,
we analysed their expression in control and SOX10-null mouse
Schwann cells and the effects of SOX10 reintroduction in
Merlin-null human schwannoma cells. SOX10-null cells show
higher expression levels of PDGFRB compared with controls cells
and also show significantly increased basal (P = 0.002) and
PDGF-induced (P50.001) rates of proliferation (Fig. 7).
In agreement with this, reintroduction of SOX10 into human
schwannoma cells greatly reduces expression of PDGFRB and
CD44 messenger RNA and protein. SOX10 re-expression also sig-
nificantly reduces basal proliferation (P = 0.03) and both PDGF
stimulated proliferation (P = 0.01) and MAP kinase signalling in
these cells (Fig. 8).
Schwannoma cells re-expressing SOX10, when viewed by fluor-
escence microscopy, showed a much more regular cell shape with
fewer filopodia and appearing to grow over each other less than
GFP control cells. Scanning electron microscopy of GFP- and GFP/
SOX10-infected schwannoma showed that SOX10 infected cells
do not overlap as frequently as control cells, displaying greater
respect for the cell membrane of neighbouring cells (Fig. 8).
The small GTPase Rac is a well-established regulator of the actin
cytoskeleton and cell morphology, including the formation of
lamellopodia. Enhanced Rac activity is a key feature of
Merlin-null murine and human schwannoma cells (Shaw et al.,
2001; Kaempchen et al., 2003). Rac activation was measured in
control GFP- and SOX10/GFP-infected human schwannoma cells
using a Rac G-LISA kit that found SOX10 re-expression caused a
small but significant decrease (0.86-fold of control levels,
P = 0.031) in GTP bound Rac (Supplementary Fig. 6).
Discussion
Roles for the merlin tumour suppressor have been characterized in
many cell types and interaction of merlin with many other proteins
regulates a diverse number of cell functions ranging from signal-
ling at the cell membrane to controlling protein degradation in the
nucleus (McClatchey and Giovannini 2005; Ammoun et al., 2008;
McClatchey and Fehon 2009; Li et al., 2010; Cooper et al., 2011).
The hallmark feature of neurofibromatosis type 2 is the occurrence
of Merlin-null vestibular schwannomas, often bilaterally, and cur-
rently there is no effective clinical treatment for these tumours
(Hanemann, 2008). Whereas a lot is now known about the
transcription factors and signalling that control normal Schwann
cell–axon interaction, cell cycle exit and differentiation, little is
known about how merlin loss impacts on these processes and
leads to tumour development. We have performed a number of
experiments to examine the process of differentiation and cell
Figure 7 Loss of SOX10 alone in mouse Schwann cells results in
phenotypes typical of human schwannoma cells. (A) Western
blot of SOX10fl/fl mouse Schwann cells infected with GFP- or
Cre-expressing adenoviruses, showing increased expression of
PDGFRB in SOX10-null mouse cells. (B and C) Scanning electron
Micrsocopy showing flattening of SOX10-null cells (C) in
comparison with control cells (B). Scale bar = 10 mm. (D and E)
Immunolabelling of control (D) and SOX10 null (E) cells with
paxillin antibody (Pax) to reveal increased numbers of focal
adhesions in SOX10 null cells (E). Scale bar = 20 mm. (F) Graph
showing significantly (P50.001) increased proliferation of
SOX10-null mouse Schwann cells in response to 10 ng/ml of
PDGF or PDGF plus 2mM of forskolin (PDGF/For).
Reintroduction of SOX10 into SOX10-null cells once more
decreases PDGF-induced proliferation.
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cycle exit in human Merlin-null schwannoma cells. The zinc finger
transcription factor KROX20 is a key regulator of Schwann cell
differentiation, regulating both cell cycle exit and the gene expres-
sion that drives myelination (Topilko et al., 1994; Zorick et al.,
1999; Parkinson et al., 2004, 2008). The normal control by
KROX20 of cell cycle exit and myelin gene induction, using
enforced KROX20 expression, is unchanged in Merlin-null
schwannoma cells, but the ability of these cells to induce en-
dogenous markers of differentiation, such as KROX20 and
OCT6, in response to a myelination cue is markedly reduced,
implying a Merlin-dependent loss of correct signalling upstream
of KROX20. The mouse SC4 immortalized Merlin-null schwan-
noma cell line has been widely used in understanding the biology
of merlin (Morrison et al., 2007; Hennigan et al., 2012).
Interestingly, in SC4 cells, we did not observe a significant increase
in either periaxin expression or downregulation of c-Jun when
KROX20 was expressed (data not shown). We presume that the
additional genetic events in the immortalization of these cells pre-
clude their normal differentiation in response to KROX20 in con-
trast to primary human Schwann or schwannoma cells.
The transcriptional control of OCT6 and KROX20 have been
well characterized in Schwann cells, and both rely on the high
mobility group transcription factor SOX10 for their expression in
developing Schwann cells (Ghislain and Charnay 2006; Finzsch
et al., 2010; Reiprich et al., 2010; Bremer et al., 2011).
Correspondingly, we have found reduced levels of SOX10 mes-
senger RNA and protein in all the human schwannoma tumours
we have examined, and in further confirmation of the role of
SOX10, re-expression of SOX10 in human schwannoma cells
reverts many of the changes seen in these cells back to a
normal phenotype, critically including restoring the capacity to
express myelin proteins in vitro and suppressing basal and
PDGF-induced proliferation.
To separate the effects of merlin and SOX10 loss in Schwann
cells, we have used small interfering RNA and mice with condi-
tional alleles of these genes, and, both in vitro and in vivo, we see
that loss of merlin has no apparent direct effect on SOX10 ex-
pression in Schwann cells. Analysis of the role of SOX10 in
Schwann cells in vivo has shown that it is required for normal
Schwann cell–axon interaction, cell cycle withdrawal, expression
of both OCT6 and KROX20 and the normal induction and main-
tenance of myelination in peripheral nerves. In addition, loss of
SOX10 leads to an increase in other cell types within the nerve,
such as endothelial cells and pericytes and an apparent decrease in
S100-expressing Schwann cells (Finzsch et al., 2010; Bremer et al.,
2011), although we, in agreement with other studies (Rosenbaum
et al., 1998; Kanaan et al., 2008), find no decrease in S100
staining in the schwannoma tumours we have analysed; in accord-
ance with this, we find no increase in S100b messenger RNA levels
when SOX10 is re-expressed in schwannoma cells (data not
shown).
Our examination of SOX10-null mouse Schwann cells in vitro
shows that loss of SOX10 alone replicates phenotypic changes
associated with human schwannoma cells, such as increased num-
bers of focal adhesions, increased proliferation and increased
expression of and signalling through the PDGF receptor beta
Figure 8 Re-introduction of SOX10 reduces PDGFRB and CD44 levels, reduces PDGF-induced signalling and prevents cell overgrowth in
human Merlin-null schwannoma cells. (A–D) GFP-control- (A and B) and GFP/SOX10- (C and D) infected human schwannoma cells were
immunolabelled with PDGFRB antibodies. SOX10 causes clear downregulation of membrane staining for PDGFRB. Scale bar = 20 mm.
(E) Western blot showing that adenovirally mediated re-expression of SOX10 lowers PDGFRB protein levels in schwannoma cells.
(F) Semi-quantitative PCR- of duplicate complementary DNA samples prepared from two independent human schwannoma cell cultures
infected with control GFP or GFP/SOX10 adenoviruses. Note that downregulation of CD44 and PDGFRB messenger RNAs following
SOX10 re-expression. (G) SOX10 reexpression in human schwannoma cells reduces PDGF-induced ERK1/2 MAP kinase activation.
Human schwannoma cells infected with either control GFP or GFP/SOX10 adenoviruses were treated with PDGF-DD for 15 min. Blotting
with HA antibody shows exogenously re-expressed SOX10 protein. (H) Re-introduction of SOX10 reduces both basal and PDGF-induced
proliferation of human Merlin-null schwannoma cells at 72 h. (I–L) Immunolabelling of control GFP-infected (I and J) human schwannoma
cells shows clear membrane-associated staining of CD44 (arrows in J), which is lost on SOX10 re-expression (K and L). Scale bar = 20 mm.
(M and N) Scanning electron microscopy of GFP- (M) and GFP/SOX10- (N) infected human schwannoma cells. Scale bar = 10 mm. Note
that control cells frequently overgrow one another, upon SOX10 re-expression the cells appear to respect cell–cell boundaries.
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(PDGFRB). From these data, we would propose a model by which
loss of Merlin and SOX10 contribute to the phenotype of human
schwannoma cells. For the example of the PDGFRB, loss of Merlin
in cells only causes a modest (1.3-fold) increase in PDGFRB mes-
senger RNA levels but is involved in recycling of the receptor pro-
tein at the cell surface (Lallemand et al., 2009), whereas our data
show that SOX10 appears to transcriptionally repress the PDGFRB
gene; thus, the combined effects of both merlin and SOX10 loss
will lead to the large increases seen in PDGFRB protein levels in
human schwannoma cells. Similarly, for CD44 messenger RNA,
which encodes the hyaluronate receptor that transmits proliferative
signalling in Merlin-null cells (Morrison et al., 2001; Bai et al.,
2007), SOX10 transcriptionally represses CD44 messenger RNA
levels when reintroduced into human schwannoma cells.
The mechanism by which SOX10 expression is lost in human
schwannomas is unclear; the simplest explanation would be that
loss of merlin leads to changes in cell signalling that repress SOX10
transcription, but our in vitro and in vivo analysis show this to not
be the case. Analysis of both Merlin-null knockout cells and Merlin
re-expression experiments in human schwannoma cells shows
that the acute loss of Merlin has no effect on levels of SOX10.
What regulates SOX10 in Schwann cells is presently unclear,
but an upstream enhancer, known as U3, contributes to SOX10
expression and can be activated by a number of transcription
factors such as SOX10, SOX9, AP2 (TFAP2A) and FOXD3
in vitro (Wahlbuhl et al., 2012). A role for activated Notch
has also been shown in repressing SOX10 expression in
Schwann cells (Li et al., 2004), and Merlin loss in Drosophila
leads to increased Notch signalling (Maitra et al., 2006), but
inhibition of Notch signalling by the -secretase inhibitor N-[N-
(3, 5-difluorophenacetyl)-lalanyl]-S-phenylglycine t-butyl ester;
25 mM of the -secretase SOX10 expression in schwannoma cells
(data not shown).
The key to the loss of SOX10 in human schwannomas, we
propose, may be the chromosomal location of SOX10 and
Merlin on chromosome 22. Remarkably, the two genes are close
to one another on the long arm of chromosome 22 (merlin
22q12.2, SOX10 22q13.1). The second ‘hit’ and loss of merlin
function in neurofibromatosis type 2 commonly involves loss of
heterozygosity or a large deletion of chromosome 22, and our
meta-analysis of cytogenetic studies on schwannoma tumours in-
dicates that the region encoding SOX10 would be lost in 450%
of these tumours (Bruder et al., 1999; Antinheimo et al., 2000;
Mantripragada et al., 2003; Koutsimpelas et al., 2011), although
this is probably an underestimate as the chromosomal marker
resolution of several of these studies is not particularly good.
SOX10 has been shown to bind and activate its own promoter
(Wahlbuhl et al., 2012); therefore, it is possible that the loss of
one allele could lead to the transcriptional silencing of the remain-
ing intact allele in Schwann cells and the corresponding fall in both
SOX10 messenger RNA and protein observed in schwannoma tu-
mours. Another alternative, which has been proposed, given the
differences observed between patients with neurofibromatosis
type 2 and the phenotype of mice with Merlin-null Schwann
cells, is that there is a third ‘hit’ at another locus in addition to
the loss of merlin (Woods et al., 2003). Such an additional genetic
change could directly or indirectly affect SOX10 expression and
contribute to the phenotype we observe in human schwannoma
cells. The production and characterization of a conditional SOX10
allele, and the separation of merlin and SOX10 on different mouse
chromosomes (chromosomes 11 and 15, respectively) would now
allow the testing of the effects of SOX10 hemizygosity or com-
plete loss on the biology of Merlin-null cells and may lead, per-
haps, to the development of a mouse model that more closely
matches the human disease.
In conclusion, we have identified consistent loss of SOX10 in
human schwannoma cells, and our results identify that this loss
strongly contributes to the phenotype of this tumour cell type.
These results, for the first time, provide a direct link between
the processes involved in normal Schwann cell differentiation
and homeostasis in the peripheral nerve and the development
and pathology of schwannoma tumours. Further characterization
of the relative contributions of merlin and SOX10 to the biology of
schwannoma cells may give important insights into how to treat
these clinically important tumours.
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